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The fact that cancer is a leading cause of death all around the world has naturally 
sparked major efforts in the pursuit of novel and more efficient biomarkers that could 
better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the 
battle against this type of disease. Mass spectrometry-based proteomics has proven 
itself as a robust and logical alternative to the immuno-based methods that once 
dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches 
such as the natural gap between shotgun discovery-based methods and clinically 
applicable results have called for the implementation of more direct, hypothesis-based 
studies such as those made available through targeted approaches, that might be able 
to streamline biomarker discovery and validation as a means to increase survivability of 
affected patients. In fact, the paradigm shifting potential of modern targeted proteomics 
applied to cancer research can be demonstrated by the large number of advancements 
and increasing examples of new and more useful biomarkers found during the course of 
this review in different aspects of cancer research. Out of the many studies dedicated 
to cancer biomarker discovery, we were able to devise some clear trends, such as 
the fact that breast cancer is the most common type of tumor studied and that most 
of the research for any given type of cancer is focused on the discovery diagnostic 
biomarkers, with the exception of those that rely on samples other than plasma and 
serum, which are generally aimed toward prognostic markers. Interestingly, the most 
common type of targeted approach is based on stable isotope dilution-selected 
reaction monitoring protocols for quantification of the target molecules. Overall, this 
reinforces that notion that targeted proteomics has already started to fulfill its role as a 
groundbreaking strategy that may enable researchers to catapult the number of viable, 
effective, and validated biomarkers in cancer clinical practice.
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CANCeR AND HOw PROTeOMiC TOOLS 
CAN Be OF HeLP
Cancer remains a major cause of mortality worldwide, despite 
continuous progress in detection, diagnosis, and therapy of these 
maladies (1–3). According to the World Health Organization, 
more than 14.1 million new cancer cases and 8.2 million 
cancer-associated deaths were reported globally in 2012, while 
it is estimated that we will see an increase of over 70% new 
cases during the next two decades. Lung tumors remain the 
most common type of cancer in the world, both in terms of 
new cases and fatalities while breast cancer is the second most 
common cancer overall, but ranks fifth as cause of death due to 
the relatively favorable prognosis; these are followed, as related 
to incidence, by colorectal cancer (CRC) and prostate cancer (4). 
Early diagnosis improves the likelihood of successful treatment 
and can be lifesaving. The obvious epidemiological relevance of 
cancer has led to the publication of many studies, but only about 
30 molecular tumor biomarkers are currently recommended in 
clinical practice guidelines across all cancer types, which serves as 
a statement to just how urgent it is to find more and better cancer 
biomarkers (5–7).
Diagnostic biomarkers are highly important for early detec-
tion and diagnosis of cancer, making their discovery an urgent 
requirement for improving outcomes. The complexity and 
heterogeneity of cancer makes it clear that the disease evolves 
via multiple pathways and it is actually the result of a combina-
tion of tumorigenesis, tumor relapse, and metastasis, involving 
complex protein networks and clinical events. Since malignant 
transformation that culminates in cancerous cells involves 
changes in protein expression, posttranslational modifications, 
and degradation, all of which in turn influence the molecular 
circuitry in these cells, it stands to reason that protein analysis 
is a good way of identifying modifications and interactions 
through which the disease evolves (4).
Proteins are ubiquitous molecules involved in virtually every 
single biological phenomena, from providing cell structure to 
closely regulating host responses to infection and inflammation 
(8). One can then assume that unraveling the many interactions 
between these molecules is paramount to better understand and 
intervene in any disease process, including cancer. Proteomic 
studies are needed to cope with such a daunting task, since the 
mere extrapolation of genomic data has proved to be insufficient 
in making sense of the real-world complexity of the interaction 
and function of biological processes regulated by proteins. 
This is because mechanisms such as allosteric regulation, post-
translational modifications, alternative splicing, and dynamic 
protein–protein interactions render genetic prediction tools 
incomplete, since they cannot accurately predict protein abun-
dance or activity (9). Recent developments in pathway analysis 
provide ways to gather insights into the biology of the identified 
genes and proteins in cancer patients who can be associated with 
a phenotype by genomic analysis. Thus, new information can be 
obtained from global analyses of proteins. Integrated genomics 
and proteomics analyses provide a more well-rounded view of 
cancer biology and are able to generate better predictions for 
clinical phenotypes. The advent of new technologies to study 
the genome gave birth to several tools, including proteomics, 
that can better serve the purpose of understanding the bio-
logical processes behind cancer. In that sense, studies based on 
proteomic analysis help to systematically and simultaneously 
identify different proteins expressed in a given cell type or bio-
logical fluid, while enabling the monitoring of posttranslational 
modifications, structural changes, and other interactions involv-
ing proteins (10).
The adoption of proteomic approaches represents a shift in the 
general strategy to unravel the processes involved in cancer. For 
a long time, many laboratories around the world used the identi-
fication or quantification of specific protein species as predictors 
of the physiological states of cancer cells (11), primarily through 
immunological assays, such as ELISA, Western blot (WB), and 
other immunohistochemistry (IHC)-based tools to quantify indi-
vidual proteins. However, these types of quantification methods 
are laborious and costly and often do not allow multiplexed assays 
nor represent the absolute abundance of the actual biomarkers in 
a biological sample (12, 13).
Proteomic tools, on the other hand, have greatly progressed 
over the years and have, in more than one instance, replaced 
the aforementioned methods in the study of cancer biomark-
ers. The first report of a proteomic analysis of cancer was 
based on a two-dimensional gel electrophoresis (2DGE) run 
that had selected spots identified by matrix-assisted laser 
desorption ionization mass spectrometry (MS). A total of 11 
proteins were identified in lysates of human A375 melanoma 
cells (14). Gel-based proteomics has greatly contributed for 
significant development in cancer research, more specifically 
on the study of colorectal (15), pancreatic, and breast cancer 
(16, 17). Throughout the last decade, gel-based experiments have 
been partially replaced by MS-based techniques, due to some 
advantages of the latter. Nevertheless, 2DGE-based approaches 
are still used in cancer research (18) and have been shown 
to possess a few specific advantages, as recently published 
by Rogowska-Wrzesinska et  al., despite it being a laborious 
and time-consuming method that presents lower throughput 
when compared to liquid chromatography-mass spectrometry 
(LC-MS)-based proteomics (19).
The design of new strategies for sample fractionation, labe-
ling, processing, and analysis through bioinformatic tools, com-
bined with the ever-increasing speed and sensitivity of the latest 
generation of mass spectrometers have propelled the proteomic 
field of study to a point in which it is feasible to identify, quantify, 
and monitor robust sets of data regarding protein biomarkers 
expression, posttranslational modifications, and other molecu-
lar aspects of cancer that may be clinically relevant. Being able 
to compare the ratios of protein abundance, posttranslational 
modifications, complex formation, and protein interaction 
networks, among disease states, generates a wide range of pos-
sibilities for studying the progression of cancer. These kind of 
studies have been of the utmost importance for the development 
of novel diagnostic and therapeutical tools, while also enabling 
a better understanding of the processes that occur during the 
progression of cancer (20).
There are many ways to go about conducting a proteomics-
based investigation of cancer and recently a paradigm shift has 
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been taking place, in which a clear maturing of the technology 
can easily be seen coexisting with changes in the dynamics of 
both discovery-based (i.e., shotgun proteomics) and hypothesis-
based (i.e., targeted proteomics) methods. In the following pages, 
we not only dwell on the general aspects of these different 
proteomic approaches but also provide a wide range of examples 
on just how targeted proteomics has already provided inspiring 
results in the search of novel and useful biomarkers relevant to 
different aspects of cancer research. Out of the more than 100 
studies reviewed in the present text, we were able to compile a 
comprehensive table that shows how different proteomic tools 
have already broken the surface of streamlined biomarker 
discovery through the use of a variety of samples in several 
types of cancer. An expanded and unabridged version of these 
findings can be seen in Tables 1 and 2, at the end of the present 
review. Some of these studies are more deeply discussed in the 
section dedicated to describing biomarker discovery in specific 
types of cancer.
PROTeOMiC STUDieS AND THe TiMeLY 
SHiFT FROM CLASSiC TO MODeRN 
STRATeGieS
Shotgun Proteomics
Within MS-based proteomics, discovery-based experiments, 
also known as shotgun proteomics, are still the most widely used 
approaches and can be further categorized into two major groups: 
label-based technologies (using isotopic or isobaric tags) and 
label-free (LF) MS-based proteomics (134). Discovery strategies 
are frequently used to obtain a broad overview of the proteins in a 
comparative analysis of different cellular characteristics in cancer, 
such as distinct invasiveness and proliferation, and it has been 
previously used as a valid tool for high-throughput biomarker 
discovery in which efficient clinical validation may or may not 
be achieved (135).
Classic, or shotgun, proteomic tools and strategies, albeit 
highly efficient in terms of sorting out hundreds or even thou-
sands of proteins involved in any given number of biological 
states and possibly comparing separate experimental conditions, 
lack an intuitive or direct connection to steps involving hypoth-
eses formulation, since it seldom involves narrower questions 
regarding the changes undergone by specific molecules within 
the different conditions studied. Rather, traditional proteomic 
experimental designs are conceived in order to come up with 
complex answers to somewhat non-specific questions, i.e., 
identifying a huge number of proteins that might be up- or 
downregulated in different experimental conditions. While this 
general design has allowed ongoing advances in a number of 
medical subjects, it usually falls short of providing clinically 
relevant, practice-changing information and more often than 
not, fails to provide promptly available tools for better diagnosis 
or treatment of diseases. This is at least in part due to the 
fact that the extremely complex results of shotgun proteomic 
studies bear an inherent gap toward the more specific ques-
tions that might be of use for creating novel diagnostic steps 
or therapeutical strategies.
In common workflows for shotgun proteomics, proteins 
(either labeled or not labeled with stable isotopes) are enzymati-
cally digested and the resulting peptides are separated by single 
or multi-dimensional chromatography to be later injected into 
a tandem mass spectrometer for ionization and analysis. Inside 
the mass spectrometer, the ionized peptides are driven by 
electromagnetic fields and analyzed according to their mass-
to-charge ratio (m/z) and precursor ions can then be selected 
for fragmentation by different MS/MS methods. The ionized 
fragmented peptides undergo another step in order to have their 
m/z determined. After the steps above, thousands of MS and 
MS/MS spectra are obtained and can provide information about 
the amino acid sequences of the peptides and the relative (or in 
some cases, absolute) abundance of the respective proteins in the 
original sample (20, 136, 137).
Although this approach promotes the identification of thou-
sands of proteins in a single experiment with high accuracy and 
resolution (11), it holds grave limitations in real-life scenarios. 
One major caveat of shotgun proteomics is the fact that digested 
and fragmented peptides are usually represented relative to 
the abundance of each protein in the sample, causing the most 
abundant proteins to be more likely identified, while possibly 
overlooking less abundant proteins (138). The stochastic nature 
of precursor ion selection also represents a serious limitation of 
discovery-based proteomics since it limits the reproducibility of 
these types of assays. A final relevant obstacle for the propaga-
tion of these strategies in biomolecular studies is the fact that 
classic proteomic studies are technically challenging, limiting 
the number of laboratories that can cope with its many technical 
difficulties (9).
The unique technical limitations and strengths of shotgun 
or discovery-based proteomics have established an unforeseen 
stalemate: an increasing number of basic-science laboratories 
have been applying powerful MS tools in a perpetual cycle of 
proteomic identification, which does not serve a particularly 
clinically applicable cause, usually not culminating in propos-
ing novel surrogate endpoints; on the other hand, laboratories 
involved in more hypothesis-driven and clinically applied 
research tend to rely in less accurate protein identification/
quantification methods, such as western blotting and other 
antibody-based assays (9, 139). To further corroborate the 
current state, it has been demonstrated that the bulk of papers 
reporting findings in specific human proteins are focused on a 
relatively or disproportionately small number of molecules and 
that the advent of genome sequencing and the resulting growth 
in proteomic techniques has not changed this imbalance in a 
relevant fashion (139), making it clear that the mere identifica-
tion of a humongous number of proteins present in different 
biological conditions is not enough to provide potentially 
clinically applicable results. Rather, a more targeted, hypothesis-
driven approach, that takes into consideration known biological 
data should at some point work alongside this broader way of 
looking at the proteome.
According to the Merriam-Webster dictionary, the scientific 
method is defined by principles and procedures for the systematic 
pursuit of knowledge involving the recognition and formulation 
of a problem, the collection of data through observation and 
TABLe 1 | A compilation of some of the most relevant studies that made use of samples from human cancer patients for the search of molecular biomarkers relevant to the diagnosis, prognosis, 
and/or therapeutical strategies in cancer research.
Reference Type of 
cancer
Methodology Sample Patients Statistically validated targets Type of 
biomarker
Prefractioning/
enrichment
Target selection Number 
of 
targets
Mass 
spectrometry 
(MS) 
approach
Controls Cancer Protein iD Number 
of 
proteins
(21) Bladder – Isobaric tags for relative 
and absolute quantitation 
(iTRAQ) shotgun 
proteomics
63 Stable isotope 
dilution-
selected 
reaction 
monitoring 
(SID-SRM)
Urine 80 76 Adiponectin, Afamin, apolipoprotein 
A-II precursor, CERU, complement 
C4 gamma chain; prothrombin
6 Diagnostic
(22) Breast Affinity depletion of 14 
abundant proteins
Label-free (LF) shotgun 
proteomics
34 SID-SRM Plasma 4 – – – Diagnostic
(23) Breast SCX iTRAQ shotgun proteomics SID-SRM and 
LF-SRM
Tissue 13 19 Decorin; endoplasmin; 40S 
ribosomal; alpha actin; 14-3-3 
zeta-delta
49 Prognostic
(24) Breast Affinity depletion of 
abundant proteins
Transcriptomics; 
cell culture shotgun 
proteomics; bioinformatics
107 Labeled 
reference 
peptide 
(LRP)-SRM
Plasma – 76 Fibronectin, clusterin, gelsolin and 
α-1-microglobulin/Inter-α-trypsin
Prognostic
(25) Breast Immunoprecipitation LF shotgun proteomics 4 SID-SRM Serum; 
Tissue
56 56 PDCD4, CGN, G3BP2, OCIAD1 4 Therapeutic
(26) Breast 2D-LC Cell culture shotgun 
proteomics; literature
319 SID-SRM Tissue – 244 CLTC, DPYSL2; ABAT; many others Diagnostic; 
prognostic
(27) Breast Enrichment for membrane 
proteins
iTRAQ shotgun proteomics 49 SRM Tissue – 27 MFAP4; GP2 23 Prognostic
(28) Breast SCX; Fe-IMAC iTRAQ shotgun proteomics 19 SID-SRM Tissue – 12 PDS5; T1208; S352; S417; S13 15 Prognostic
(29) Breast – Transcriptomics database; 
LF shotgun proteomics;
20 SID-SRM Tissue – 96 KPNA2; CDK1 2 Prognostic
(30) Breast – LF shotgun proteomics 3 LF-SRM Plasma 204 216 ApoA1; hemopexin; angiotensin; 
preprotein
3 Diagnostic
(31) Breast Off-gel IEF iTRAQ shotgun 
proteomics; western 
blotting
3 SID-SRM Tissue 10 10 Cofilin-1; p23 2 Prognostic
(32) Breast – Cell culture shotgun 
proteomics; literature
1 SID-SRM Tissue – 40 HER2 Diagnostic; 
prognostic
(33) Breast Precipitation and 
ultrafiltration
Literature 5 SID-SRM Plasma 20 20 IGF1, IGF2, IBP2, IBP3, and A2GL 5 Diagnostic
(Continued )
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Reference Type of 
cancer
Methodology Sample Patients Statistically validated targets Type of 
biomarker
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enrichment
Target selection Number 
of 
targets
Mass 
spectrometry 
(MS) 
approach
Controls Cancer Protein iD Number 
of 
proteins
(34) Breast – LF shotgun proteomics 100 LF-pSRM Tissue – 51 ENPP1; UQCRFS1; GNB4 – Therapeutic
(35) Breast SPE Literature 6 SID-SRM Serum 6 6 Hyp3-bradykinin; Des-Arg9-
bradykinin; Fib-α; C4a; ITIH4; 
Bradykinin
6 Diagnostic
(36) Breast Affinity depletion of 
abundant proteins; 
immunoaffinity enrichment
Literature 1 SID-SRM Serum 60 60 sTfR-transferrin receptor 1 Therapeutic
(37) Breast Membrane protein 
extraction
Literature 1 SID-SRM Tissue – 60 P-gp 1 Prognostic
(38) Colon SDS-PAGE Literature 60 18O SID-SRM Feces 5 5 L-plastin, filamin A, S100A9, 
hemoglobin, myeloperoxidase
5 Diagnostic
(15) Colon SDS-PAGE, RP, and SEC 
HPLC
LF shotgun proteomics 40 SID-SRM Feces 7 8 a-1-antityrpsin, a-1-acid 
glycoprotein, complement C3, 
fibrinogen, haptoglobin, hemoglobin 
a, hemoglobin b, myeloblastin, 
transferrin
9 Diagnostic
(39) Colon Affinity depletion of 
6 abundant proteins; 
SDS-PAGE
LF shotgun proteomics 8 LF-SRM Plasma 48 48 CLU 1 Diagnostic
(40) Colon – Literature 7 SID-SRM Serum 259 172 ORM1, GSN, C9, HABP2 SAA2, C3 6 Diagnostic
(41) Colon Ultracentrifugation and 
filtration to select NOP
LF shotgun peptidomics 1 SID-SRM Urine 25 24 Collagen type 1 1 Prognostic
(42) Colon Laser microdissection; 
SDS-PAGE
Literature 22 SID-SRM Tissue – 3 B-catenin; c-Src; c-Myc; PP2A 4 Prognostic
(43) Colon Cell membrane 
fractionation
iTRAQ shotgun proteomics 105 SID-SRM Tissue 16 33 ITGA5, GPRC5A, PDGFRB, TFRC, 
Others (see Table 2)
44 Diagnostic; 
prognostic; 
therapeutic
(44) Colon – Literature 3 Hyperplex-SRM Tissue – 37 AHCY, CTSD, LYZ 3 Prognostic
(45) Endometrial SCX iTRAQ shotgun proteomics 1 mTRAQ-SRM Tissue 1 1 PK 1 Diagnostic
(46) Gastric Laser microdissection Literature 1 SID-SRM Tissue – 130 MET 1 Prognostic; 
therapeutic
(47) Glioblastoma – Transcriptomics; shotgun 
proteomics; literature
100 SID-SRM Tissue – – Malectin; calnexin; LDHA; IDH; and 
many others
32 Therapeutic
(Continued )
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(48) Kidney – – – SWATH Tissue 9 9 – – Diagnostic
(49) Liver Lectin enrichment for 
glycoproteins
Literature 10 SID-SRM Plasma 30 10 AACT, A1AT, A1AG1, CERU 4 Diagnostic
(50) Liver Lectin enrichment for 
glycoproteins
Literature 2 SID-SRM Plasma 3 3 A1AT; FETUA Diagnostic
(51) Liver – cDNA microarray; copy 
number variation; somatic 
mutation; epigenetic; 
quantitative proteomics 
data
50 LRP-SRM Serum 36 36 ANLN; FLNB; C4A; AFP 4 Diagnostic
(52) Liver Affinity depletion of 6 
abundant proteins
Literature 1 SID-SRM Serum 95 60 AFP 1 Diagnostic
(53) Liver mHFER enrichment for 
glycopeptides
shotgun proteomics 49 iCCM-SRM Serum 10 3 14
(54) Liver Affinity depletion of 6 
abundant proteins
LF shotgun proteomics 4 SID-SRM Plasma 10 1 AGP; vitronectin; afamin precursor; 
Kininogen1 precursor
4 Diagnostic; 
prognostic; 
therapeutic
(55) Liver – Literature 2 SID-SRM Plasma 40 41 Vitronectin; AGP 2 Diagnostic
(56) Liver Aptamer-based 
fractionation
Gel-based proteomics 1 SID-SRM Serum 24 26 ApoA1 1 Diagnostic; 
prognostic
(57) Liver Aptamer-based 
proteominer depletion of 
abundant proteins
2D-DIGE 43 SID-SRM Serum 6 6 AFP, AFP-L3, DCP – Diagnostic
(58) Liver SDS-PAGE LF shotgun proteomics 31 SID-SRM Tissue – 50 DDX39; FBLN5; MARCKS; 
SERPINH1; VCAN
5 Diagnostic
(59) Liver Hp affinity isolation Literature 1 SID-SRM Plasma 20 10 Haptoglobin-T3 1 Prognostic
(60) Liver – Literature 2 O18-SID-SRM Serum 10 10 CLU-1; VIT-2 2 Prognostic
(61) Lung Lectin fractionation Literature 2 SID-SRM Plasma 33 33 AGP, CP 2 Prognostic
(62) Lung Affinity depletion of 6 
abundant proteins
LF shotgun proteomics 34 SID-SRM Pleural 
effusion
86 39 ALCAM, CDH1, MUC1, SPINT1, 
THBS4
5 Diagnostic
(Continued )
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(63) Lung Enrichment for 
desthiobiotinylated and 
tyrosine-phosphorylated 
peptides
LF shotgun proteomics 264 LRP-SRM Tissue 5 5 Kinases Therapeutic
(64) Lung Microdissection Literature 1 SID-SRM Tissue – 23 EGFR 1 Therapeutic
(65) Lung Affinity depletion of 
albumin and IgG
Literature 95 SID-SRM Plasma 72 30 ACTN1; ALDOA; ENO1; FLNA; 
G6PD; GPI; HSP90B1; ICAM1; ILK; 
LDHB; MSN; PGK1; PKM2; SPP1; 
TALDO1; THBS1; ZYX
17 Diagnostic
(66) Lung Affinity depletion of 
albumin and IgG
Literature 371 SID-SRM Plasma 123 124 ISLR; BGH3; FIBA; TSP1; TETN; 
COIA1; LG3BP; LRP1; FRIL; PRDX1; 
GRP78; ALDOA; GSLG1
13 Diagnostic
(67) Lung Immunoaffinity Databases, literature 5 SID-SRM Serum 12 12 TIMP1, SLPI, TFPI, TFPI2, and CEA 5 Diagnostic
(68) Lung Laser microdissection LF shotgun proteomics 6 In sample 
internal 
standard-SRM
Tissue – 27 Napsin-A, hAG-2 2 Prognostic
(69) Lung – LF shotgun proteomics 705 LF-SWATH BALF 12 12 Haptoglobin, complement C4-A, 
glutathione S-transferase
44 Diagnostic
(70) Lung – Literature 1 SID-SRM Serum 50 160 Hp (subunits α and β) 1 Diagnostic
(71) Lung – Literature 2 SID-SRM Serum 99 100 SAA1 and SAA2 2 Diagnostic
(72) Lung Immunoaffinity Literature 3 SID-SRM Serum 4 6 ProGRP isoform 1, ProGRP isoform 
3, NSE
3 Diagnostic
(73) Lung SDS-PAGE LF shotgun proteomics 10 SID, LRP, and 
LF-SRM
Tissue – – β-galactosidase; alkaline phosphatase 2 Diagnostic
(74) Melanoma SDS-PAGE Literature 1 SID-SRM Tissue – 192 BIM 1 Therapeutic
(75) Melanoma SDS-PAGE Literature 82 SRM Tissue – – HSP70; VEGFR2; mTOR; IRS-4; 
GSK3; AKT1/2
6 Therapeutic
(76) Melanoma – Literature 1 SID-SRM Tissue 0 10 SNCA 1 Prognostic
(Continued )
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(77) Mesothelial Glycopeptides enrichment MS-CSC; spectral libraries 36 LF-SRM Serum 26 49 Intercellular adhesion molecule 
1; basement membrane-specific 
heparan sulfate proteoglycan core 
protein; anthrax toxin receptor 1; 
serum paraoxonase/arylesterase 
1; hypoxia upregulated protein 1; 
thrombospondin-1
6 Diagnostic
(78) Oral – Literature 14 LRP-SRM Saliva 8 22 C1R; LCN2; SLPI; FAM49B; TAGLN2; 
CFB; C3; C4B; LRG1; SERPINA1
10 Prognostic
(79) Ovary Combinatorial peptide 
libraries 2D-LC
LF shotgun proteomics 134 LF-SRM Ascites 
fluid
– 6 AMBP, BCAM, BTD, CD109, CD14, 
COMP, CPN2, ECM1, FSTL1, 
HABP2, HSPG2, IGFBP3, KLK6, 
LBP, LGALS3BP, MIF, MSLN, MSN, 
MSRA5, PON1, PRG4, SERPINA10, 
SERPINC1, SERPIND1, SERPINF1, 
SHBG, TGFB1, THBS1, TIMP1, TNC
30 Diagnostic
(11) Ovary Affinity depletion of 
12 abundant proteins; 
MudPIT; OFFGEL
LF shotgun proteomics 51 SID-SRM Ascites 
fluid
25 5 GAPDH, MSLN, PKM1/2 3 Diagnostic
(80) Ovary Affinity depletion of 14 
abundant proteins
LF shotgun proteomics 2 SID-SRM Tissue 10 11 WDR1 1 Therapeutic
(81) Ovary Affinity depletion of 12 
abundant proteins
Literature; computational 
prediction
34 SID-SRM Plasma 68 16 AACT, APOA1, APOE, B2MG, C1R, 
CFAB, CO5, CO6, CO7, GELS, HPT, 
IC1, ITIH4, RET4, SHBG, TETN, 
THBG, TRFE, TTHY
19 Diagnostic
(82) Ovary Affinity depletion of 
20 abundant proteins; 
SDS-PAGE
LF shotgun proteomics 7 LF-SRM Plasma 15 18 3 Diagnostic
(83) Ovary Affinity depletion of 
20 abundant proteins; 
SDS-PAGE
LF shotgun proteomics 2 LF-SRM Plasma 1 3 CLIC; TPM 2 Diagnostic
(84) Pancreas SDS-PAGE Literature 1 SID-SRM Cyst 
fluid
5 10 KRAS 1 Diagnostic
(85) Pancreas – LF shotgun proteomics 18 LRP-SRM Tissue – 9 TGM2, PSAP, DPYSL3, SERPINF1, 
ARPC4, BRRP7, S100A11, CAN2, 
MVP, GC
10 Prognostic
(Continued )
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(86) Pancreas 2D-nano-HPLC iTRAQ shotgun proteomics 1 SRM Tissue 3 7 Dihydropyrimidinase-like 3 1 Therapeutic
(87) Pancreas Affinity depletion of six 
abundant proteins
Literature; database 260 SID-SRM Plasma 100 84 KLKB1, IGFBP2, THBS1, PPBP, TXN, 
LDHB, IGFBP3, LRG1, C5, AGT, 
CPN2
11 Diagnostic
(88) Pancreas Lectin affinity 
chromatography
TMT shotgun proteomics 1 SID-SRM Serum 115 26 Serotransferrin 1 Diagnostic
(89) Pancreas Membrane and cytosolic 
fractions
Literature 25 SID-SRM Tissue – 10 dCK 8 Treatment
(90) Pancreas Affinity depletion of 
albumin and IgG
Shotgun proteomics 
(literature)
5 SID-SRM Plasma 40 20 Gelsolin, lumican, TIMP1 3 Diagnostic
(91) Pancreas Laser microdissection; 
immunohistochemistry
Shotgun proteomics 170 LRP-SRM Tissue 5 8 ECH1, GLUT1 (GTR1), OLFM4, 
STML2
4 Prognostic
(92) Pancreas Streptavidin affinity 
2D-nano-HPLC
Shotgun proteomics 4 SRM Tissue 38 62 FN1, PRELP, TGM2, AGRN 4 Diagnostic; 
therapeutic
(93) Pancreas Affinity depletion of high 
and medium abundant 
proteins
SILAC shotgun proteomics 72 SID-SRM Serum 20 20 cystatin M, IGF binding protein 7, 
villin 2
3 Diagnostic
(94) Pancreas – Shotgun proteomics PTM 
(literature)
1 SID-SRM Plasma 21 70 α-fibrinogen containing Hyp-530 and 
Hyp-565
1 Diagnostic
(95) Prostate – Databases, LF shotgun 
proteomics
32 LF-parallel 
reaction 
monitoring 
(PRM)
Urine 15 15 PROS1; HPR; PZP; SLAIN1 4 Diagnostic
(96) Prostate SCX Literature 1 SID-SRM Serum – – PSA 1 Diagnostic
(97) Prostate Depletion of 14 
abundant proteins; 
immunoprecipitation
Literature 2 SID-SRM Serum – – proPSA; PSA 2 Diagnostic
(98) Prostate Glycopeptides enrichment LF shotgun 
glycoproteomics
39 SID-SRM Serum; 
Tissue
66 77 GALNTL4; FN; AZGP1; BGN; ECM1 Diagnostic; 
Prognostic
(99) Prostate Affinity depletion of 
abundant proteins; MCX
Literature 1 SID-SRM Serum 4 5 PSA Diagnostic
(100) Prostate – 2D-DIGE-MS SID-SRM Urine 14 11 Vinculin; PAP; galectin-3 3 Diagnostic; 
prognostic
(Continued )
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targets
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spectrometry 
(MS) 
approach
Controls Cancer Protein iD Number 
of 
proteins
(101) Prostate Microdissection; 
glycopeptides enrichment
LF shotgun 
glycoproteomics
548 SWATH Tissue 10 65 N-acylethanolamine acid amidase; 
protein tyrosine kinase 7
3 Diagnostic; 
prognostic
(102) Prostate High PH RP-HPLC Literature 1 SID-SRM Serum 1 2 PSA 1 Diagnostic
(103) Prostate Affinity depletion of 14 
abundant proteins; high 
PH RP-HPLC
Literature 2 SID-SRM Urine; 
serum
23 14 ARG2; PSA 2 Diagnostic
(104) Prostate Glycoprotein enrichment Literature 37 SID-SRM Serum 0 37 CPM; APOB; CADM1; CFH; CP; 
CTSD; GOLM1; TIMP1
8 Therapeutic
(105) Prostate Affinity depletion of 7 
abundant proteins
Literature 10 SID-SRM Seminal 
liquid; 
blood 
plasma
– 37 SNP-L132I 1 Prognostic
(106) Thyroid – Literature 21 LF-SRM; 
SID-SRM
Tissue 9 27 S100A6; S100A11; ANXA1; 
S100A13; S100A4; S100A10; ANXA2
7 Diagnostic; 
prognostic; 
therapeutic
A variety of different targeted proteomic methods were employed and are also described.
TABLe 1 | Continued
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TABLe 2 | A compilation of some of the most relevant studies that made use of in vitro, xenografts, or samples from non-human models for the search of molecular biomarkers relevant to the 
diagnosis, prognosis, and/or therapeutical strategies in cancer research.
Reference Type of 
cancer
Methodology Sample Species Statistically validated targets Type of 
biomarker
Prefractioning/
enrichment
Target selection Number 
of 
targets
Mass 
spectrometry 
(MS) approach
Protein iD Number 
of 
proteins
(107) Breast IMAC (phospho) SILAC shotgun 
proteomics
100 Parallel reaction 
monitoring (PRM)
MCF7, PC3, HL60 
cells
H. sapiens MAPK, PI3K/mTOR, and 
CDK
– Therapeutic
(108) Breast – Label-free (LF) shotgun 
proteomics
258 LF-SRM MCF10A cells H. sapiens CDH1; CDH2; vimentin Therapeutic
(109) Breast Phosphatase treatment Literature 4 Labeled reference 
peptide (LRP)-SRM
MCF-7 cells H. sapiens ER, HER2, RAF, and 
ERK1
4 Prognostic
(110) Breast SCX Literature 76 Stable isotope 
dilution-selected 
reaction monitoring 
(SID-SRM)
MCF-7 cells H. sapiens SLC2A1, HSPA5, LDHA, 
PGR, and TFF1
12 Prognostic
(111) Breast – SILAC shotgun 
proteomics
8 LF-PRM 231-BR; MDA-
MB-231 cells
H. sapiens MMP1; EFNB1; STOM1; 
UAP1; MYCT1; TGM2; 
S100A4; LCP1
8 Prognostic
(112) Breast Avidin-agarose Isotope-coded 
ATP-affinity shotgun 
proteomics
120 SID-SRM; isotope-
coded ATP-affinity
MCF-7 cells H. sapiens CHK1, CDK1, and CDK2 120 Therapeutic
(113) Breast Immunoenrichment; 
SDS-PAGE
Literature 1 SWATH and MS1 
filtering
SK-BR3 cells H. sapiens ErbB2 1 Diagnostic
(114) Breast Immunoprecipitation of 
decorin and periostin
Isobaric tags for 
relative and absolute 
quantitation (iTRAQ) 
shotgun proteomics
2 SID-SRM MDA-MB-231; 
T47D; BT-20 cells
H. sapiens Decorin; periostin 2 Therapeutic
(26) Breast 2D-LC LF shotgun proteomics 319 SID-SRM 30 cell lines H. sapiens CLTC, DPYSL2; ABAT; 
many others
Diagnostic; 
Prognostic
(115) Breast 2D-gel 2D-DIGE 11 LF-SRM ZR-75-1, MDA-
MB-231, and MCF-
10A cells
H. sapiens HSP105, KRT8, KRT18, 
RPLP0, and RAD23B
5 Therapeutic
(116) Breast 2D-LC iTRAQ shotgun 
proteomics
12 SID-SRM MCF7 cells H. sapiens HSPA8, LDHA, NACA, 
CTSD, PKM2, IGF-1R
6 Therapeutic
(29) Breast – Transcriptomics 
database; LF shotgun 
proteomics;
20 SID-SRM SK-BR-3 and MDA-
MB-231 cells
H. sapiens KPNA2; CDK1 2 Prognostic
(117) Breast Cell nuclei enrichment Literature 2 LF-SRM MCF-7 cells H. sapiens NF-κB2; Stat1 2 Prognostic
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Reference Type of 
cancer
Methodology Sample Species Statistically validated targets Type of 
biomarker
Prefractioning/
enrichment
Target selection Number 
of 
targets
Mass 
spectrometry 
(MS) approach
Protein iD Number 
of 
proteins
(118) Breast – LF shotgun proteomics 60 LF-SRM Tissue Mus 
musculus
Osteopontin and fibulin-2 2 Diagnostic; 
Prognostic
(119) Colon Lectin affinity Literature 2 LRP-SRM WiDr cells H. sapiens TIMP1; PTPK 2 Diagnostic
(42) Colon Laser microdissection; 
SDS-PAGE
Literature 22 SID-SRM HCT116, HT29, 
KM12, SW620, 
KM12C, KM12L4A, 
and KM12SM cells
H. sapiens B-catenin; c-Src; c-Myc; 
PP2A
4 Prognostic
(120) Colon Affinity depletion of 
3 abundant proteins; 
SCX
SILAC shotgun 
proteomics
9 SID-SRM Serum M. musculus MGAM; COL1A1; ITIH3 
and F5
4 Diagnostic
(121) Colon affinity depletion of 3 
abundant proteins; 
SCX
SILAC shotgun 
proteomics
20 SID-SRM Serum M. musculus Cysttin C, secreted 
phosphoprotein 1, 
pyruvate kinase 3, 
procollagen C-proteinase 
enhancer, nucleobindin, 
HSP1A, nucleolin, 
fibronectin, profilin, HSP8
10 Diagnostic
(122) Colon; lung; 
melanoma; 
leukemia; 
myeloma
SDS-PAGE Literature 221 SID-SRM Multiple cell lines 
(>25)
H. sapiens 95 Therapeutic
(123) Glioblastoma Secretome enrichment Shotgun 65 SID-SRM U87 cells H. sapiens EGFR, EGFRvIII, and/
or PTEN
62 Therapeutic
(124) Kidney Immunoaffinity Literature 1 SID-SRM PRC3 cells H. sapiens CA12 1 Diagnostic
(125) Kidney; 
Breast
– Shotgun 114 LRP-PRM BT474 and Sum159 
xenograft
H. sapiens HER2 104 Diagnostic
(126) Leukemia IMAC (phospho) LF shotgun proteomics 25 LF-SRM AML-193, CMK, 
CTS, HEL, 
Kasumi-1, KG-1, 
MV4-11, and P31/
FUJ cells
H. sapiens PI3K, MEK, and JAK 3 Therapeutic
(127) Lung SDS-PAGE Literature 1 LF-SRM A431 cells H. sapiens 6 phosphosites in EGFR 1 Therapeutic
(63) Lung Enrichment for 
desthiobiotinylated and 
tyrosine-phosphorylated 
peptides
LF shotgun proteomics 264 LRP-SRM HCC366 and H2286 
cells
H. sapiens Kinases Therapeutic
(Continued )
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Methodology Sample Species Statistically validated targets Type of 
biomarker
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enrichment
Target selection Number 
of 
targets
Mass 
spectrometry 
(MS) approach
Protein iD Number 
of 
proteins
(64) Lung Microdissection Literature 1 SID-SRM Xenograft cell culture M. musculus EGFR 1 Therapeutic
(128) Lung; skin; 
colon
Phosphotyrosine 
immunoenrichment
Literature 83 LRP-PRM A431; SW480 and 
11–18 cells
H. sapiens EGFR; FLK2; EPHA1; 
FAK1; FGFR2; IGF1R; 
LYN; PGFRA; PTK7; 
SRC; VGFR2; and YES
21–28 Therapeutic
(129) Multiple 
myeloma
SDS-PAGE Literature 15 SID-SRM RPMI-8226; U266 
cells
H. sapiens NF-κB1 and 2, RelB/p50, 
Bcl-2, Mcl-1, Bfl-1, Bcl-
xL, Bid, Bim, FANCD2, 
FANCI
– Therapeutic
(130) Ovary Affinity depletion of 20 
abundant proteins; IEF; 
SDS-PAGE
LF shotgun proteomics 14 LF-SRM Xenograft mouse 
models
M. musculus AGRN, PSME2, TPI1, 
DDAH2, GM2A, YWHAB, 
YWHAH, PSMA, 
PSMB1–4
Diagnostic
(131) Ovary – Literature 1 Ion-trap LRP-pSRM 2008 cell line H. sapiens SOD1 1 Therapeutic
(132) Ovary Immunoprecipitation; 
SDS-PAGE
Shotgun 2 SID-SRM OVTOKO, OVISE, 
MCAS, OVKATE, 
OVSAHO, OVMANA, 
OVSAYO, OVCAR-3, 
RMG-I, and RMG-II 
cells
H. sapiens Brg1; ARID1A 2 Diagnostic
(84) Pancreas SDS-PAGE Literature 1 SID-SRM DLD1; COLO-205; 
SW480; A549; 
HCT116; HT-29 cells
H. sapiens KRAS 1 Diagnostic
(89) Pancreas Membrane and 
cytosolic fractions—
centrifugation
Literature 25 SID-SRM PK9, CFPac-1, 
PK1, SUIT2, AsPC1 
human cells
H. sapiens dCK; UMP-CMP; cN-III; 
ENT1
4 Therapeutic
(133) Prostate – Literature 1 SID-SRM VCaP and LNCaP 
cells
H. sapiens ERG3 1 Diagnostic; 
prognostic
A variety of different targeted proteomic methods were employed and are also described.
TABLe 2 | Continued
14
Faria et al. Shotgun Proteomics Applied to Cancer Research
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 13
experiment, and the formulation and testing of hypotheses. This 
relationship between specific hypothesis postulation and its 
testing through experimentation is clearly more in sync with 
the aspects that drive targeted proteomics. It is important, 
however, to be clear that discovery proteomic methods are not 
by any means irrelevant or wasteful in nature. Such strategies 
have paved the way through which modern targeted proteomics 
travels and it could be argued that the difficulty in transitioning to 
more elegant platform for proteomic exploration from broader, 
discovery-based approaches into hypothesis-driven scenarios in 
cancer research represents a natural and predictable growing 
pain in balancing the inherent opportunity costs of each method-
ology. Shotgun approaches have indeed opened up the proteome 
for more specific, reproducible, and question-based investigation 
by targeted proteomics that may allow us to answer more specific 
questions more rapidly and more accurately than previously 
possible, in a way that impacts diagnosis and treatment of a 
number of diseases, including cancer, since targets studies are by 
definition better for streamlining biomarker discovery in real-life 
conditions. In reality, the present review demonstrates that this is 
an ongoing trend that has already helped with the identification 
of several biomarkers for a number of cancer types, regarding 
several relevant aspects of the disease, such as diagnosis, staging, 
prognosis, and therapy.
Targeted Proteomics
The concept of targeted MS assays for peptide quantitation 
originated with the study of isotopically labeled peptides used as 
internal standards to measure peptide levels in biological samples 
as early as in 1983 (140). Later, in 1990, Kusmierz et  al. (141) 
applied the acronym MRM (multiple reaction monitoring) for 
the quantification of peptides in human tissue extracts by com-
paring spectra of unlabeled samples to those of labeled peptides. 
Modern targeted approaches, generally called selected reaction 
monitoring (SRM, which can be interchangeably termed MRM) 
focus on following up the quantification of a handful of proteins 
of interest in separate experimental conditions, performing rela-
tive or absolute quantification with high specificity and sensitivity 
(46), even in particularly complex backgrounds.
To identify proteins in a targeted fashion, it is mandatory to 
monitor proteotypic peptides (PTPs), which are unique amino 
acid sequences that consistently identify a specific protein in a 
given proteome interrogated by MS (95). These PTPs serve as a 
signature for the selected protein of interest and are monitored 
throughout the experimental run. The selection of peptides, 
which best represent a protein of interest, is a crucial step in the 
analysis of the sample (20, 142, 143), since targeted proteomics 
is no more than a method for monitoring the precursor and 
fragment ions of previously selected peptides, meaning that the 
proteins under investigation must be known beforehand.
Targeted approaches are driven by specific hypothesis, so previ-
ous in-depth knowledge about the protein of interest is necessary. 
Information used to select candidate peptides to be monitored for 
targeted approaches can be of varying sources, making the use of 
previous findings in the literature or even introductory overall 
screening discovery-based proteomic assays possibly essential 
for reliable results (144). In the conventional method for SRM, 
all the information about the target peptides and parameters for 
their best separation, ionization, and fragmentation must be set 
prior to the experiment. Such strategy requires access to the host 
of information about the target proteins, since a good selection of 
PTPs and peptide fragments ensures high sensitivity and specific-
ity, as mentioned before.
The advent of targeted techniques mitigated the problem 
around quantification of low-abundance proteins inherent to 
shotgun methodology, while allowing better quantitative repre-
sentation of proteins of interest, thus representing a more sensitive 
and efficient technique as compared to conventional methods for 
the analysis of specific proteins (47, 144). The targeted approach 
is a directed and selective analysis, which allows it to function as 
a form of qualitative and quantitative validation.
Other technical advantages of the targeted approach are 
related to the selectivity and dynamic range, with the possibility 
of it being benefited from shotgun strategies in terms of data 
density and effectiveness (145). Targeted assays can also add 
multiplexing capabilities that far exceed those of immunological 
assays, though yet not comparable to discovery-based strategies. 
Usually the approaches regarding targeted proteomics are precise 
in quantitative measurements at the peptide level.
A classical targeted proteomics assay requires specific MS 
instruments like the triple quadrupole analyzer, where the first 
and third quadrupoles work as m/z filters, while the second quad-
rupole acts as a collision cell (146). The first quadrupole selects 
the previously defined PTPs based on their m/z ratio and the 
second quadrupole acts as a collision chamber, fragmenting the 
selected peptides. The precursor and product ion pairs are often 
called transitions. These fragments (product ions) are analyzed in 
the third quadrupole where they might also be further filtered for 
specific fragments to be monitored (146, 147).
Important concepts related to more advanced experimental 
strategies involve the relative and absolute quantification of 
proteins that can be achieved using targeted proteomics 
approaches. Relative quantification (also referred as differen-
tial expression) experiments provide the abundance ratio of 
proteins comparing two separate conditions, while absolute 
quantification offers the absolute molar (or mass) concentra-
tion of specific proteins in the analyte. In order to perform 
absolute quantification assays, synthetic peptides are spiked 
into the samples at known amounts for later comparison of 
the precursor and fragment peak areas of the same peptide 
between the naturally occurring molecule in the sample and 
the spiked synthetic one (148). This kind of method has been 
successfully used in cancer-targeted research by the majority 
of the authors in the present review, with few variations to 
the general method. Absolute quantification methods using 
synthetic labeled peptides are often used for validating biomark-
ers by targeted proteomics (143). The stable isotope-labeled/
stable isotope dilution (SIL/SID) methods represent the gold 
standard for rigorous proteins quantification through SRM in 
which peptides are synthesized with the insertion of stable 
isotope labels at the C-terminal Arg and Lys residues (13C6 15N4 
for Arg, 13C6 15N2 for Lys) (65, 73, 128). The most commonly 
used approach relies on isotopically labeled reference peptides 
(LRPs) that are chemically identical to the light native peptides 
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(AQUA peptides) (149). The analytical precision of this method 
is high and can result in as low as 5% errors in the estimation 
of the amount of peptide originally loaded onto the liquid 
chromatography system (150), but limitations such as cost make 
its application in broad multicandidate studies impractical. LRP 
in sample internal standard and LF quantification methods 
represent alternative tools for protein quantification in SRM 
(Figure 1), where, in case of the former and the latter, a single 
peptide (isotopically labeled or not) is used as the reference 
peptide for all other peptide analytes in the sample; and where, 
in case of the lattermost, no internal isotope is employed at all, 
so that quantification is based only on the peak areas extracted 
from the SRM product ion chromatograms (68, 73).
Another perhaps less-known targeted approach can make 
use of hybrid instruments such as quadrupole–time of flight that 
measures the m/z of the ions produced using the time of flight of 
the peptide inside a chamber under vacuum. Hybrid instruments 
as the QExactive™ (Thermo Scientific) appeared in the targeted 
proteomics scene to improve the resolving power and speed of tar-
geted analysis (65, 95). Parallel reaction monitoring (PRM) is an 
excellent choice for the monitoring of low-abundance peptides in 
biological samples. The PRM acquisition simultaneously analyzes 
all fragment products generated by peptide fragmentation. This 
method demands much less investment in optimizing the acqui-
sition schedules, because of its tolerance to coelutions between 
product ions. A more thorough description of the improvements 
to targeted proteomics that were brought about by PRM analysis 
can be found in Ref. (147). Both SRM and PRM hold an intrinsic 
limitation as to the fact that once the data for the set of peptides 
specified for the assay is acquired, there is no possibility of revisit-
ing the selection parameters to perhaps look at the data focusing 
on different targets. This can at least in part be ameliorated 
through the use of data-independent acquisition (DIA) methods, 
more specifically by the use of SWATH-MS (sequential window 
acquisition of all theoretical fragment ion), where sequential 
windowed acquisition of all theoretical ion spectra within a 
user-defined retention time and mass-to-charge ratio interval is 
achieved, so that the coverage of proteins to be monitored in a 
single assay is greatly expanded, while maintaining the advanta-
geous quantitative aspects of the target acquisition (48, 151). The 
numerous fragmented ions contained in a map created during 
this type of MS method represent a gap-free or continuous data 
set that can be used for sequential in silico hypothesis testing, even 
in cross study comparisons not envisaged in the primary studies 
(48). Moreover, the inherent properties of the DIA-based aspect 
of SWATH-MS allow for indefinite remining of the fragment ion 
spectra using classic target analysis strategies (152), which theo-
retically allow for increased robustness in biomarker discovery, as 
shown in a later part of the present review.
The association of different immunoenrichment methods 
alongside SRM has been used in cancer biomarker discovery in 
testicular, prostate, and lung tumors (153). Accurate validated MS 
methods are essential for the application of targeted proteomics 
in any personalized clinical decisions as reviewed by Abbatiello 
and colleagues (154). High-resolution instruments can provide 
increased selectivity of targeted analysis over SRM and allow for 
the simultaneous execution of both discovery and verification 
phases and accurately provide mass measurements, which trans-
lates into improved selectivity by discriminating more efficiently 
the targeted peptides from the interferences of complex biological 
matrices (155).
The National Cancer Institute (USA) started the Clinical 
Proteomic Tumor Analysis Consortium (156), tasked with 
evaluating targeted and discovery technologies for quantitative 
analysis in tissues and biofluids in order to identify proteins that 
are related to alterations consequent to cancer, serving as a public 
resource that facilitate access to well-established assays and accel-
erates the standardization of the technology. Several specialized 
software, such as Skyline and ATAQS, have been developed to 
support the application of SRM assays and optimize data analysis 
over the years (157, 158).
Important large-scale studies have demonstrated the high 
reproducibility of multiplexed SRM assays performed across 
multiple laboratories and instrument platforms. With standard-
ized protocols for sample preparation, data acquisition, and 
analysis, intra- and interlaboratory coefficients of variation in the 
range of 10−25% were achieved. LoD (limit of detection) and 
LoQ (limit of quantification) values observed in unfractionated 
plasma were in the high hundreds of nanograms per milliliter 
to low micrograms per milliliter concentration ranges for target 
proteins and had a linear dynamic range spanning three orders 
of magnitude (22).
Below, we describe several applications where targeted prot-
eomics have in one way or another provided relevant information 
for the advancement of cancer research, ranging from novel 
biomarker discovery, all the way to patient stratification, disease 
prognosis, and treatment. It is important however to stress that 
methods involving antibody selection of proteins, such as reverse-
phase protein arrays (RPPA), were not within the proposed scope 
of our discussion.
TARGeTeD PROTeOMiCS iN CANCeR
As shown above, targeted proteomics generates data that comple-
ment and enhance pathology diagnosis in cancer. Variations in 
protein concentration provide information that connects geno-
type to phenotype. These type of data are of pivotal importance 
in understanding biological processes in complex diseases such 
as cancer, which involves the orchestrated interactions of multiple 
genes and proteins (159).
The most clinically relevant and therefore ideal output from 
proteomics research is obviously the reliable identification and 
quantification of cancer surrogate endpoints (i.e., biomarkers 
validated to predict clinical outcome in an accurate and reproduc-
ible manner) in easily accessible patient biofluids, such as plasma, 
serum, saliva, tears, urine, or feces (160, 161). In reality, different 
kinds of molecular targets have been used to discover biomarkers 
in blood/plasma/serum, body fluids, tissues, and their secretions 
(162). Plasma is a particularly attractive sample source for disease 
biomarker discovery and early disease prediction, but character-
izing the proteome of biological fluids presents daunting chal-
lenges due to the extreme complexity and large dynamic range in 
protein concentrations inherent to these types of samples (162). 
The choice of plasma or serum as a base sample is an important 
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FiGURe 1 | Distribution of the number of studies using targeted approaches according to the methods used, further grouped by the use of sample 
enrichment prior to RP-LC-MS.
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consideration when developing blood-based biomarker assays, 
since the expression or availability of individual proteins for pro-
cessing may vary greatly between these media. This conundrum 
becomes evident when one acknowledges the lack of consensus 
among protein biomarker studies (10). Additionally, inter- and 
intratumoral heterogeneity observed in cancer studies represent 
yet another obstacle for the discovery and validation of clinically 
relevant biomarkers.
Targeted approaches are specifically promising for this 
endeavor due to the possibility of accurate protein quantification 
and validation in a large number of complex samples, where 
high-sensitivity MS-based targeted proteomics can be used to 
overcome some of the aforementioned obstacles.
Some successful applications of SRM/MRM-based proteomics 
on a variety of biological samples from clinical specimens have 
been achieved. Tissue-based targeted proteomics applied to 
cancer plays an important role in disease staging and represents 
a potential source of candidate biomarkers for early cancer 
diagnosis, while also playing an important role in enabling large 
retrospective biomarker discovery and verification. Nevertheless, 
it suffers from a number of drawbacks regarding reproducibility, 
scalability, and feasibility of mining formalin-fixed paraffin-
embedded (FFPE) biobanks for candidate biomarkers (125). In 
addition, targeted MS workflows applied to FFPE samples are 
complementary to techniques requiring high-quality antibodies, 
such as IHC or RPPA. As for IHC and RPPA, SRM relies on the 
measurement of the target protein by measuring one or ideally 
several surrogate peptides (143).
Chen et al. accomplished a quantitative SRM protein analysis 
of urine samples, resulting in 12 proteins with higher concentra-
tion in bladder cancer patients when compared to control samples 
(21) in a pioneering study in 2012. Multiplexed SRM analysis gen-
erated a six-peptide marker panel involving adiponectin, afamin, 
apolipoprotein A-II precursor, complement C4 gamma chain, 
and prothrombin, all of them theoretically able to discriminate 
bladder cancer patients from non-cancerous individuals.
In addition, enrichment of target proteins before SRM has 
proven to be useful for reliable quantification (Figure 1) in the 
low microgram per liter range, with several studies showing LoQs 
below the microgram per liter range, even in relatively complex 
backgrounds. In this context, immunoextraction with antibodies 
immobilized on a hydrazide resin, followed by digestion of the 
immunoprecipitated proteins with tandem isotopic-labeled SRM 
assays, has resulted in low microgram per liter quantification 
of proteins such as carcinoembryonic antigen in lung cancer 
through blood serum samples and found spiked levels of other 
proteins such as tissue factor pathway inhibitor 2 and secretory 
leukocyte peptidase inhibitor (67).
Although many candidate molecules have been proposed 
over the hundreds of studies published, only 23 protein 
plasma biomarkers have been cleared by the US Food and 
Drug Administration (FDA) since 2003 as clinical biomarkers 
averaging less than two proteins per year over the last 12 years 
(163). Among the FDA-approved or -cleared cancer biomarker 
proteins, nine are exclusively designed for serum and six others 
are applicable to either plasma or serum. Recent SRM studies for 
cancer biomarker verification show a similar trend regarding the 
proportion of potential biomarkers found in serum and plasma 
samples (164, 165). Despite recent technical advances, there are 
still huge analytical challenges for clinically relevant identifica-
tion of biomarkers in serum or plasma.
Studies have previously suggested that whole blood-based 
targeted proteomic profiling is capable of screening and iden-
tifying biomarkers for diagnostic, prognostic, and therapeutic 
purposes. In truth, several reports can be found in which a 
host of different sample types are used as alternative sources of 
data for investigating cancer biology and identifying potential 
biomarkers, although in-depth quantitative profiling of human 
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plasma samples for biomarkers discovery remains quite chal-
lenging. Analyzing the studies selected on Table 1, it is possible 
to find eight predominant human sample types studied by 
targeted proteomics, among which, tumor tissue and whole- 
or fractionated-blood are the most often studied (Figure  2B). 
Together, these studies demonstrate that robust, reproducible 
targeted proteomic and subsequent pilot-scale validation stud-
ies can be accomplished using LF quantification strategies. 
Promising results include the findings from Keshishian et  al., 
whom have shown detection limits of target proteins in the 
range of picograms per milliliter after depletion and sample 
fractionation of the plasma proteome (150). One lingering 
challenge of SRM for candidate biomarker verification is the 
required sensitivity for quantification of low-abundance proteins, 
given a dynamic concentration range of plasma proteins of over 
12 orders of magnitude (166, 167).
It is clear that applying targeted proteomics to the discovery 
of novel biomarkers with real-life potential of impacting medical 
practice is a daunting task. The drastic heterogeneity or large 
biological variations such as gender, age, genetic factors, dietary 
considerations, environmental factors, and drug treatment 
often hinder the discovery and establishment of gold standard 
biomarkers that can be applied to screen the overall population 
(10). Nevertheless, several research groups have been able to 
contribute to this effort in a variety of cancer types. Below we 
describe examples of these advancements regarding particularly 
relevant types of tumors and the biomarkers that were either 
proposed or validated during these assays. Upon careful analysis 
of the data, it is possible to discern interesting trends. Out of the 
100-plus studies examined in Tables 1 and 2, most were dedi-
cated to studying biological aspects of breast cancer (Figure 2A). 
Second, most biomarkers were related to diagnostic applications 
in favor of prognostic or therapeutical targets (Figure 2B), with 
the exception seen when the sample source consisted of assays 
that made use of actual tumorous tissue, where a great dedication 
toward prognostic biomarkers was evident (Figure 2C). Finally, 
most of the reports were based in classic SID-SRM quantifica-
tion, although other less common techniques were also described 
(Figure 1).
Breast Cancer
As previously stated, breast cancer is the second most common 
type of tumor in the human population worldwide, so it stands 
to reason that great focus has been given to the subject in recent 
times, with targeted proteomics providing invaluable insights 
regarding diagnosis, monitoring, and therapy of this kind of can-
cer (Figure 2A). Narumi et al. applied large-scale phosphopro-
teome analysis and SRM-based quantitation to develop a strategy 
for the systematic discovery and validation of biomarkers using 
tissue samples for breast cancer (28). Through immobilized metal 
affinity chromatography and isobaric tags for relative and absolute 
quantitation (iTRAQ) isotopic labeling techniques, they identi-
fied phosphopeptides that were differentially abundant between 
high- and low-risk recurrence groups of breast cancer predicted 
by MammaPrint, an FDA-approved breast cancer recurrence 
assay. The identified phosphopeptides were validated by SRM, 
indeed augmenting MammaPrint prediction capabilities. This 
systematic approach holds enormous potential for the discovery 
of bona fide disease biomarkers in cancer research.
Despite the progress made to date in treating breast cancer, the 
constant changing dynamics of its incidence requires continuous 
investigation to identify new methods for detection and treat-
ment. In this context, an SRM-based study by Pavlou and collabo-
rators in 2014 suggested that higher levels of 4-aminobutyrate 
aminotransferase (ABAT) could be related to better prognosis 
in breast cancer patients, specifically those who are ER positive, 
tamoxifen treated, and with grade II staging (29). The somewhat 
small sample cohort (N = 20) in addition to the fact that ABAT 
is yet to be studied in the specific context of breast cancer make 
it hard to readily export these findings into a clinical scenario.
Shaheed et al. identified proteins whose expression correlate 
with breast cancer progression and validated candidate profiles of 
benign, non-invasive, and invasive breast tumors using discovery 
proteomics, with the use SRM for validation (31). The results cor-
roborated previous reports of higher levels of cofilin-1 and p23 
and lower levels of membrane copper amine oxidase (AOC-3) in 
invasive carcinoma patients when compared to normal controls. 
In addition, the results have indicated that proteomic analysis 
of matched tissues can generate a valuable subset of candidate 
proteins for further investigation.
A handful of studies have focused on analyzing metastatic 
behavior through targeted proteomics. In one study by Cawthorn 
et al. the differentially abundant proteins identified in an iTRAQ-
2DLC-MS/MS experiment were validated by LF SRM on breast 
tumor tissue sample set (N  =  32) (23). Together with tissue 
microarray analysis data, SRM results indicated the correlation 
between higher levels of decorin and endoplasmin and the pres-
ence of lymph node (LN) and distant metastases.
By using a targeted approach employing MIDAS, a SRM 
assay was successfully designed based on a limited set of in silico 
predicted transitions in a study aimed at identifying protein level 
changes in MCF-7 cells in response to temporal IGF-1R stimula-
tion, where ENO1 showed up at higher levels in breast cancer 
cell versus their normal counterparts; ENO1, PKM2, and LDHA 
were also upregulated in both invasive MDA-MB-231 cells and in 
IGF-1-induced MCF-7 cell, which indicated IGF-1 involvement 
in tumor invasiveness (116).
One study by Greenwood and colleagues in 2012 demon-
strated a panel of markers differentially expressed in LN-positive 
and -negative tumors that enabled further classification into 
two phenotypes regarding the expression of signal transducer 
and activator of transcription 1-alpha/beta (STAT1), interferon-
induced GTP-binding protein Mx1, and leukocyte surface 
antigen CD74. Cellular functional assays showed that interferon-
induced upregulation of STAT1 was associated with increased cell 
migration and invasion while CD74 overexpression resulted in 
increased cell adhesion (168). The authors suggest that targeting 
the pool of CD74 expressed at the plasma membrane could be 
a viable strategy for stratified therapy of triple-negative breast 
tumors overexpressing Stat1 and CD74.
Colorectal Cancer
Colorectal cancer is the most common gastrointestinal malig-
nancy worldwide and the third leading cause of cancer-related 
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deaths, which makes the discovery and validation of novel 
biomarker candidates for this type of cancer of the utmost 
importance for improving disease detection in routine surveil-
lance and screening protocols. Ang and colleagues were able to 
create a SRM library of PTPs that was applied to the screening of 
fecal samples from eight CRC patients and seven healthy controls. 
The abundance of 40 proteins of interest selected from a prelimi-
nary discovery-based approach was monitored during the assay 
(15). Nine proteins were exclusive for the fecal samples of CRC 
patients, of which only hemoglobin and a-1 antitrypsin had been 
previously proposed as CRC biomarkers. The remaining seven 
proteins had not been previously explored as fecal biomarkers. 
The aforementioned group of nine proteins now represent a 
novel candidate biomarker panel proposed for the detection of 
CRC with similar or higher sensitivity than the presently avail-
able commercial immunoassays and serve as an option to the 
standard fecal occult blood screening test which has well-known 
high false-positive and false-negatives rates. This protein panel, 
if proven to be validated in a larger cohort of samples, could be 
reengineered into antibody-based assays, compatible with cur-
rent clinical analyzers.
Pancreatic Cancer
The diagnosis of pancreatic ductal adenocarcinoma is particu-
larly challenging since the disease tends to be asymptomatic. 
Therefore, the investigation of the pancreatic cancer proteome 
has gained considerable attention over the years. A study by 
Pan et al. quantified four proteins differentially expressed in the 
plasma of 20 patients in early stages (I and II) of pancreatic cancer 
in comparison to 40 controls, half of which had chronic pancrea-
titis, which shares many clinical symptoms with this type cancer 
(90). Of the four proteins that were quantified by SRM, tissue 
inhibitor of metalloproteinase 1 (TIMP1) was also measured by 
ELISA. The authors suggest that the SRM assay measured total 
TIMP1, while the ELISA measured only free TIMP1, neglecting 
molecules bound to self-directed antibodies or other protein 
complexes.
In this context, Yoneyama et  al. examined two proline-
hydroxylated sites in alpha-fibrinogen as potential biomarkers 
for pancreatic cancer (94). Concentration of alpha-fibrinogen 
remained constant among 27 healthy controls and 70 cancer 
patients, while concentrations of specific hydroxylated peptides 
and hydroxylation ratios were both increased in cancer patients 
(p < 0.05). The hydroxylated alpha-fibrinogen peptides had area 
under the curve (AUC) values of 0.650 and 0.668, respectively, 
both of which were below the AUC value (0.903) for the FDA-
approved pancreatic biomarker, CA19-9.
A couple of studies in 2011 and 2013 reported by Turtoi 
et  al. and Takadate et  al. made use of shotgun LF quantifica-
tion of pancreatic cancer tissues with poor and better survival 
outcomes, and non-cancerous pancreatic ducts (91, 92). 
Both studies selected targets for SRM protein quantification. 
Among these, 14 proteins were found to be upregulated in 
pancreatic cancer compared to normal tissue. Patients whose 
tumors expressed the proteins enoyl-CoA hydratase 1 (ECH1), 
olfactomedin-4 (OLFM4), stomatin-like protein 2 (STML2), 
and glucose transporter member 1 (GLUT1 or GTR2) had 
significantly worse survival rates, suggesting that these 
proteins may be of prognostic value, and may serve as new 
therapeutic targets. Kawahara and collaborators reported the 
use of proteomic profiling through iTRAQ for identifying a 
number of proteins differentially abundant between cancerous 
and normal pancreatic duct epithelium, with higher abundance 
of dihydropyrimidinase-like 3 (DPYSL3) in human pancreatic 
cancer (86). Given that it has important roles in regulating the 
motile phenotype of pancreatic cancer cells, DPYSL3 may be a 
candidate for antimetastasis therapeutic strategies, which may 
ultimately lead to a reduction in the large number of deaths 
caused by this devastating disease.
Hepatocellular Cancer
Hepatocellular carcinoma (HCC) mortality is high because early 
detection is hampered by the high inaccuracy, cost, and proce-
dural risks of the available tests, which creates an urgent need 
for minimally invasive, highly specific, and sensitive biomarker 
candidates that enable early disease detection while therapeutic 
intervention is still potentially beneficial. Lee et  al. targeted 
non-glycopeptide candidates for identification and validation of 
molecular markers among glycoproteins in human plasma (55).
Ahn et  al. studied plasma samples of hepatocellular cancer 
patients via a lectin-coupled SRM approach based on fucose-
specific aleuria aurantia lectin fractionation of glycoproteins prior 
to SRM (49). The study yielded glycoforms of tissue inhibitor of 
metalloproteinase 1 (TIMP1) and protein tyrosine phosphatasek 
(PTPk), which play important roles in invasive and metastatic 
cancer cells and are known targets of N-acetyl glucosaminyl 
transferase (GnT-V). The results obtained using lectin-based 
glycoprotein enrichment coupled to SRM shed light on biomark-
ers capable of distinguishing plasma from HCC patients and 
non-cancerous controls and that aberrant glycoforms of TIMP1 
and PTPk were upregulated in GnT-V-overexpressing cells in 
comparison with their control counterparts.
Kim et al. measured the total amount of AFP (non-glycopep-
tide level) and the degree of glycosylated AFP in human serum 
using an SRM assay (52). This assay proved that the quantification 
of deglycosylated AFP has much better sensitivity and specificity 
toward differentiating HCC cancer samples from controls when 
compared to measurements of total AFP. Another study using 
an SRM approach focused on the verification of vitronectin and 
clusterin, confirming their significant downregulation in human 
hepatocellular cancer serum versus normal control serum (60). 
Mustafa and colleagues have validated and confirmed reduced 
levels of ApoA1 in blood samples of HCC patients versus hepatitis 
C virus-infected patients (57). ApoA1 is known to suppress neu-
trophil activation and inhibit endothelial expression of adhesion 
molecules (169) and its downregulation may thus lead to HCC, 
indicating its role as a possible biomarker for HCC diagnosis, 
prognosis, and monitoring.
Prostate Cancer
Biomarkers that offer the possibility of detecting early onset of 
disease progression or that can differentiate between tumors 
that remain dormant and those that will eventually develop into 
aggressive invasive malignancies would provide opportunities 
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for an earlier as well as a more targeted intervention, avoid-
ing unnecessary costly treatments and overall improving 
survivability.
Geisler et al. determined the amount of prostatic acid phos-
phatase (PAP), vinculin, and galectin-3 by SRM specific to the 
urine of control patients, non-relapsing prostate cancer patients, 
and relapsing prostate cancer patients. PAP was significantly 
higher in the urine of cancer patients, galectin-3 was verified as 
a prognostic biomarker candidate and secernin-1 has been vali-
dated as a diagnostic tissue biomarker with WB analysis (100).
Ovarian Cancer
Huttenhain et al. proposed additional sample preparation steps 
aimed toward reducing sample complexity in order to achieve 
detection of proteins below the low nanograms per milliliter 
concentration range with the use of existing MS technologies 
in the study of ovarian cancer (81). The resulting SRM library 
was applied to accurately and reproducibly quantify 34 known 
cancer biomarkers with demonstrated reproducibility between 
62 ovarian cancer and 16 benign ovarian tumor patients. 
Moreover, the authors discovered a long set of cancer-associated 
proteins, among which 83 and 169 were detected, respectively, in 
plasma and urine samples. The proteomic data were submitted 
to the Peptide Atlas SRM Experiment Library, and the SRM 
assay coordinates were made publicly available for use in future 
cancer studies. The ever growing size of the data provided by 
SRM will help close the translational gap present in the valida-
tion of potential biomarkers, since it allows for the monitoring 
or simply identification of candidate biomarkers thought the 
use of a set of SRM coordinated in different laboratories and 
instrument platforms.
The FDA has approved human epididymis protein 4 (HE4) as 
a marker for monitoring recurrence or progression of epithelial 
ovarian cancer (15). Reliable clinical evidence demonstrates that 
MS-based proteomics of plasma and serum for the identification 
of HE4, alone or in combination with CA125, improves accuracy 
of routine screening. The CA125 blood test was granted FDA 
clearance for use as a monitoring response test in detecting 
residual or recurrent epithelial tumors in patients after their first-
line therapy has failed (170).
Drabovich and Diamandis have used combinatorial peptide 
libraries in the discovery phase of their proposed experimental 
design to target low-abundance proteins with LC-MS/MS data-
dependent discovery methods and identified low-abundance 
proteins in ovarian cancer ascites, which were further verified 
by SRM (79). Kallikrein 6, metalloproteinase inhibitor 1, mac-
rophage migration inhibitor factor, follistatin, and mesothelin 
were all present in the samples.
Another study analyzed multiple isoforms of seric chloride 
intracellular channel protein (CLIC1 and CLIC4) and tropomyo-
sin (TPM1-4) as potential biomarkers for ovarian cancer (82). 
The CLIC1/CLIC4 ratio varied by more than twofold in some 
samples, with AUC values for CLIC1 and CLIC4 of 0.86 and 0.79, 
respectively. The AUC values for TPM were dependent on the 
particular isoform, with 0.72 for TPM3 and 0.81 for TPM4.
Haslene-Hox et  al. performed a complex comparative prot-
eomics assay to find differentially expressed proteins in interstitial 
fluid from ovarian carcinomas compared to endometrial cancer 
and to healthy tissues (80). Levels of six candidate proteins 
(CEACAM5, FREM2, MUC5AC, TFF3, PYCARD, and WDR1) 
were further monitored in individual tumor lysates from ovarian 
carcinomas using MIDAS, WB, and/or SRM. The conclusion of 
the orbitrap assays was that WDR1 protein was significantly more 
abundant in interstitial fluid from ovarian carcinomas versus 
controls.
Lung Cancer
Lung cancer is one of the most common types of cancer and has 
very poor prognosis and high mortality and so it is naturally 
a common target for proteomic research. Kim et al. quantified 
96 potential non-small-cell lung cancer (NSCLC) biomarkers 
in NSCLC patient versus plasma from the control group (21, 
51, 65, 131). An SRM assay quantified 28 transcriptional 
factors (TF) across eight lung cancer cell lines, revealing 14 
differentially abundant TF. Seventeen proteins with high plasma 
levels were further verified using SRM in a large sample set 
and one of these proteins, zyxin, was proposed as a candidate 
biomarker of early NSCLC diagnosis. The haptoglobin beta-
chain (70) and serum amyloid A (SAA) (171) were elsewhere 
identified as new possible diagnostic markers for lung cancer. 
Park et  al. compared and quantified serum levels of target 
proteins in patients with and without NSCLS by ESI-MS/MS. 
They identified significantly higher level of HP-alpha chain in 
lung cancer patients.
A handful of studies utilizing target proteomics for the 
discovery of biomarkers involved in lung cancer metastasis 
have been made public to date. Nishimura et al. used SRM-MS 
techniques to further validate their introductory discovery pro-
teomics findings in a set of lung adenocarcinoma FFPE tissues, 
where a panel of stage IA and IIIA specific protein levels was 
demonstrated (68). The results showed hAG-2 as significantly 
more abundant in stage IIIA metastatic LN when compared to 
stage IA primary lesions.
Li and colleagues have presented a 13-protein blood-based 
categorization tool for differentiation of benign and malignant 
nodules using SRM (66). These proteins (LRP1, BGH3, COIA1, 
TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, 
FIBA, and GSLG1) are likely regulated by a group of transcrip-
tional regulators (nuclear factor erythroid 2-related factor 2, aryl 
hydrocarbon receptor, myc, and c-FOS) related to lung cancer. 
Such tool can be used to prevent patients with benign lung nodules 
from undergoing invasive procedures such as biopsy and surgery.
Sung et  al. quantified SAA isoforms SAA1 and SAA2 and 
demonstrated their elevated levels in lung cancer patient serum 
when compared to healthy controls, both through SRM and 
ELISA (71).
Thyroid Tumors
Martínez-Aguilar et  al. used SRM for the profiling of isoform-
specific expression of the calcium-binding protein S100 in the 
three most common tumors of the thyroid gland in comparison 
with normal thyroid tissues (106). Results from SRM analyses 
were confirmed by metabolic SILAC labeling and WB analysis 
and allowed the identification of S100A31 as a novel biomarker 
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candidate for papillary thyroid carcinoma. Additionally, the 
ability to discriminate between follicular and papillary thyroid 
tumors though monitoring of S100A6, S100A4, and annexin A1 
levels was described.
Targeted Proteomics and Cancer 
Response to Therapy
A number of studies have attempted to decipher the therapy or 
drug-induced proteomic changes in cancer, aiming to improve 
our understanding of the function of drugs and underlying 
mechanisms for therapy resistance in cancer. Cancer cells can 
become resistant to drugs in two major ways: the cancer itself 
changes through mutation so that the targeted therapy is no longer 
efficient and/or the tumor cells activate alternative molecular 
pathways that promote tumor growth in a way not influenced 
by therapeutical intervention. It is important to stress that in this 
instance the term targeted is more loosely applied, as the same 
word can be used for different therapeutical strategies that do not 
necessarily involve targeted proteomics.
In a study from 2014, the discovery of components in resist-
ance pathways resulted in several drug-target candidates that 
have the potential to be used to overcome resistance to the 
original medication (75). The authors successfully used SRM-
based quantitative proteomics to evaluate drug response and 
predict resistance mechanisms in melanoma. In this context, 
XL888 treatment reduced tumor growth drastically showing a 
significant decrease in the expression of proteins from the PI3K/
AKT/mTOR signaling pathway, suggesting that this pathway 
may be alternatively activated to compensate for BRAF inhibi-
tion. Moreover, they monitored the molecular response of two 
NRAS mutant melanoma cell lines submitted to treatment with 
a MEK inhibitor, AZD6244. Treatment with AZD6244 only 
led to marginal cell growth inhibition. The results showed that 
AZD6244 treatment generated a molecular fingerprint with 
increased Wnt/β-catenin signaling, NFκB phosphorylation, 
and upregulation and phosphorylation of PDGFR-β, a receptor 
tyrosine kinase (RTK).
Paraiso et al. showed another example of the PI3K/AKT path-
way being involved in drug resistance (74). By using SRM, they 
discovered a mechanism by which melanoma cells with BRAF 
mutation and PTEN loss can escape from BRAF inhibition. 
Inhibitors of BRAF have been developed and recently approved to 
treat melanoma harboring activated V600E BRAF mutation that 
is identified in more than 50% of melanoma cases. A subgroup of 
patients with BRAF-mutated melanoma showed limited response 
to these inhibitors due to intrinsic resistance. In this study, SRM-
based proteomics helped to identify the pivotal signaling node in 
the resistance mechanism by efficiently monitoring the expres-
sion of a group of selected proteins following drug treatment 
and consequently showed solid evidence for the development of 
combination therapy in melanoma treatment.
Zhang et  al. performed a comprehensive study to uncover 
EGFR phosphorylation sites correlating with somatic mutation 
and/or erlotinib (EGFR inhibitor) sensitivity in lung cancer 
cell lines (73). Three phosphorylation sites (Y1110, Y1172, and 
Y1197) connected to erlotinib sensitivity were validated using 
IP-SRM in lung cancer tissue samples; Y1197 phosphorylated 
peptides showed good signal, which confirmed that IP-SRM 
strategy is suitable for EGFR phosphorylation measurement. 
In a follow-up study, phosphorylation sites of EGFR were 
also monitored using SRM and their sensitivity to tyrosine 
kinase inhibitor (gefitinib) in the presence/absence of EGF 
was investigated.
Held and collaborators used MS1 filtering from shotgun 
proteomics data and SWATH-MS for quantification of tyrosine 
kinase ErbB2 from SK-BR-3 cells and its modified forms in breast 
cancer, reporting reproducibility of workflows with different 
proteases and indicating quantitative competitiveness of SWATH 
with SRM methods (113).
De Marchi et  al. investigated the dynamics and variability 
of the protein response to the drug tamoxifen in human breast 
cancer (25). They identified proteins whose dynamics differed 
widely between cells, in a way that corresponded to the outcomes 
of either cell death or survival. Upon assessing peptide abundance 
differences between patient groups in the primary breast cancer 
tissue confirmatory dataset, only PDCD4 and CGN peptides 
were found differentially abundant. This study opens the way to 
understand molecular responses to drugs in individual cells. In 
tamoxifen-treated breast cancer patients, high levels of EIF3E 
were significantly associated with prolonged progression-free 
survival and with therapy resistance. These efforts resulted in the 
identification of a putative protein profile that is associated with 
the type of response to tamoxifen therapy. Umar et al. validated 
the protein EMMPRIN in an independent patient cohort and 
confirmed its association with tamoxifen therapy resistance 
in recurrent breast cancer (34). Using the same quantitative 
approach, Yang and colleagues applied iTRAQ-MS and SRM 
techniques to investigate innate resistance to bortezomib, which 
is a proteasome inhibitor approved for multiple myeloma treat-
ment (37, 172). Differentially expressed proteins identified in the 
MS analysis were selected for subsequent SRM-MS quantifica-
tion, from which they successfully identified that myristoylated 
alanine-rich C-kinase substrate (MARCKS), a substrate of 
protein kinase C (PKC), is a key mediator of drug resistance. 
Inhibition of MARCKS activity by a PKC inhibitor enzastaurin 
or siRNA-mediated knockdown significantly enhanced the 
sensitivity of resistant myeloma cell lines and primary myeloma 
samples to therapy. They showed that MARCKS inhibition com-
bined with bortezomib treatment could overcome bortezomib 
resistance and effectively inhibit tumor growth in a multiple 
myeloma xenograft model. Their findings provide a new bio-
marker for the prediction of patients who are likely to have 
response to bortezomib, meanwhile also developed a rationale 
for a combination therapy targeting proteasome and MARCKS 
simultaneously, in order to improve the outcome of patients with 
refractory multiple myeloma.
Xiang et  al. used cell line models of multiple myeloma to 
investigate drug resistance of melphalan by comparing signal-
ing, apoptosis-regulating, and DNA repair component proteins, 
finding a nuclear factor-kappaB signature (129). Drug-resistant 
cell lines exhibit consistent decreases in initiators and sensitizers, 
when compared with naïve cell lines, indicating that potential 
for induction of apoptosis may be reduced by decreasing their 
abundance. This important information could help define the 
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molecular basis for personalized cancer treatment in some 
patients.
In the context of glioblastoma (GBM), the quest for find-
ing useful biomarkers is vital, once this is the most aggressive 
primary brain tumor, presenting remarkable neo-angiogenesis 
capabilities in addition to cellular and molecular heterogeneity. 
As a means to investigate proteins that are altered by antiangio-
genic treatment, thereby providing biomolecular signatures of 
tumor response in GBM, one study identified marker proteins 
that are altered during treatment and may serve as a short-
term readout of antiangiogenic therapy (47). These included 
malectin, calnexin, calreticulin, lactate dehydrogenase (LDH), 
and isocitrate dehydrogenase (IDH). The authors addressed 
the tumor escape mechanisms to bevacizumab and reported 
that LDHA was found to be induced by the treatment, while 
the upregulation of malectin and calnexin had not yet been 
previously connected to antiangiogenic treatment. The induc-
tion of LDHA was not only seen in tumor cells but also in the 
non-neoplastic host compartment, an observation that was 
possible due to the species-specific SRM workflow established 
in said study. Whether the modulation of malectin, calnexin, 
and calreticulin is a result of hypoxia-induced ER stress in 
response to bevacizumab remains to be determined. The authors 
speculate that glycoprotein production and maturation may be 
affected by antiangiogenic treatment, suggesting that glycopro-
teins could serve as important response markers. In addition, 
the establishment of a panel of target proteins modulated upon 
antiangiogenic therapy may provide the robustness required 
for biomarker-based patient stratification. By demonstrating 
that GBM-relevant alterations in the EGFR pathway distinctly 
change the secreted profile of invasion-promoting proteins as 
well as the expression and phosphorylation status of intracellular 
proteins, Sangar et  al. investigated the effects of EGFR signal-
ing on the secreted levels of proteins implicated in aggressive 
invasiveness and proliferation of GBM cells (123). Additionally, 
levels of intracellular and secreted proteins clearly showed that 
EGFRvIII carrying cells are functioning under higher oxidative 
stress. These results confirm that introduction of EGFR signaling 
proteins influences the expression as well as phosphorylation 
status of multiple proteins in the EGFR network, resulting in 
differences in the signal transduction to the nucleus (123).
Alcolea et  al. reported (i) the emerging notion that cancer 
cells are not always dependent on single oncogenes, (ii) that 
markers of PI3K and MEK pathway activities are poor predictors 
of response to PI3K and MEK inhibitors, respectively, (iii) that 
kinase pathways can cooperate to drive cancer cells proliferation 
in some systems, and (iv) that a combination of inhibitors may be 
more effective in arresting cancer cell growth when compared to 
agents that target single kinases (126).
Guo et  al. observed a breast cancer MCF7 cell population 
(MCF + FIR) that could survive after a course of clinical frac-
tionated doses of radiation and showed enhanced radioresistance 
compared to the wild-type parental MCF7 cells (112). The kinases 
play pivotal roles in triggering breast cell cycle checkpoints and 
regulating cell cycle progression. In addition, some of these 
kinases are also actively engaged in the phosphorylation of media-
tors in DNA repair pathways. Thus, the above findings of global 
kinome alterations associated with radioresistance provide new 
knowledge in understand tumor adaptive radioresistance and 
offer potential targets to sensitize cancer cells toward radiation 
therapy and to achieve better remission of cancer.
Kim et  al. tried to identify mechanisms of drug resistance 
involving alterations in protein kinase (PTK) signaling pathways 
in a lung tumor cell model of acquired resistance to the PTK 
inhibitor erlotinib (128). PTK expression varies between different 
types and stages of cancer and alterations in PTK expression is 
an important mechanism of resistance to targeted cancer thera-
peutics. These considerations suggest that multiplexed, targeted 
analysis of PTK expression profiles could be valuable in studying 
mechanisms of drug susceptibility and resistance.
CONCLUSiON
Targeted proteomics has evolved into an invaluable tool in can-
cer research and a viable field for the identification of new and 
improved biomarkers for the development of better diagnostic 
and therapeutical strategies. It is a technique that can be applied 
for the precise, accurate, and sensitive quantification of relevant 
proteins in a range of clinical materials, such as tissues and other 
bodily fluids and has enabled wondrous developments in areas 
such as gene therapy, drug target discovery, and personalized 
therapy.
The clinical and molecular heterogeneity of cancer currently 
presents clinicians with difficult problems when choosing adju-
vant treatment for individual patients. Nevertheless, a huge num-
ber of studies have provided novel candidate biomarkers in a host 
of cancer types that may serve as more efficient therapeutical or 
diagnostic targets. The fact that targeted proteomics approaches 
are generally reproducible across different platforms allows for 
the synergistic effect that may allow for an ever growing increase 
in the discovery of clinically relevant biomarkers.
A major obstacle for the use of target biomarkers in clinical 
practice is the requirement for extremely sensitive and specific 
candidates, which is currently far from perfect. There is a clear 
issue regarding sensitivity, which is dealt with by some authors 
through the use of immunoenrichment steps on sample prepara-
tion while others rely on the use of crude samples to avoid loss 
of low-abundance components. An additional pitfall is that the 
ability to analyze large sample sets is still lacking. The overall 
sensitivity and specificity shortcomes of target methodologies can 
only be surpassed through development of more robust multi-
plexing capabilities, allowing for multiple markers to be detected 
at once and for many patients to be screened within a reasonable 
time frame. SWATH (151), NeuCode (173), and Hyperplexing 
(44, 174) may not be already inserted in the clinical trials, but 
are a step toward the right direction in addressing these aspects. 
Another significant issue is the fact that candidate biomarkers 
seldom bring satisfactory clinical response. It is necessary to 
develop optimized workflows in which high-quality results are 
filtered through and interaction between researchers and physi-
cians is made possible (175).
We firmly believe that such progress in clinical proteomics 
will pave the way for greater success by accumulating and 
sharing knowledge and experience for better understanding 
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